Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma

The ad-ESD trial is phase III randomized trial to compare adjuvant esophagectomy and chemoradiation for patients with clinical stage N0 and pathological stage T1b squamous cell carcinoma (after endoscopic submucosal dissection).

Trial Details

NCT ID
NCT04135664
Phase
PHASE3
Sponsor
Shanghai Chest Hospital
Status
RECRUITING
Cancer Type
Esophageal Cancer
Interventions
  • esophagectomy
  • chemoradiation
  • active surveillance
Locations (sample)
  • Nanchang, Jiangxi, China|28.68396,115.85306
  • Shanghai, China|31.22222,121.45806
  • Shanghai, China|31.22222,121.45806
  • Shanghai, China|31.22222,121.45806
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Biopsy proven with esophageal squamous cell cancer.
  • Clinical N0 stage diagnosed by imaging examinations.
  • Pathological T1b stage confirmed by endoscopic submucosal dissection.
  • Age: 18-75.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →